News
Joshua Wolf Joins Thesis Capital Partners
HOUSTON — January 13, 2026 — Thesis Capital Partners today announced that Joshua Wolf has joined the firm. Wolf will lead investment origination and deal execution alongside the firm's Operating Partners, as well as support value creation initiatives and capital formation efforts.
Wolf brings nearly two decades of transaction experience. He spent eight years as a Managing Director at Cetane Associates, contributing to 45 successful sell-side M&A engagements, helping each business owner navigate a competitive sale and closing process. He subsequently founded JWC Sponsor Advisory Services, advising independent sponsors on deal structuring and capital formation. Earlier in his career, he held roles in energy finance at Mizuho Corporate Bank, ABN AMRO, and Crédit Lyonnais. He holds a BBA from Emory University.
"Josh brings extensive experience and deep knowledge of the full transaction lifecycle, and in particular the sponsor ecosystem, which will help us execute our strategy with discipline and speed," said Ian Reynolds, Founder and Managing Partner of Thesis Capital Partners.
Wolf added: "Thesis has built a differentiated platform — one that leads with talent and is genuinely built to own businesses for the long term. I'm excited to help source and close the kinds of transactions that fit that thesis."
More From Thesis
Related Insights
News
Thesis Capital Announces Founding Investment in LegacyVector Media
Thesis Capital Partners announces LegacyVector Media, a special situation investment focused on building unique data sets in the U.S. lower middle market.
News
Thesis Capital Partners Announces Launch of Thesis Partners II
Thesis Capital Partners announces Thesis Partners II, targeting up to $150 million to invest in founder-owned U.S. lower middle market businesses.
News
Thesis Capital Announces 2026 EIR Cohort Fully Allocated; SIR Program Now Primary In-Residence Pathway
The 2026 Entrepreneur-in-Residence cohort is fully allocated. The Searcher-in-Residence program is now the primary in-residence pathway.